Head to Head Review: Mymd Pharmaceuticals (QCLS) versus Its Rivals

Mymd Pharmaceuticals (NASDAQ:QCLS) is one of 82 public companies in the “Technology Hardware, Storage & Peripherals” industry, but how does it weigh in compared to its competitors? We will compare Mymd Pharmaceuticals to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Mymd Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	-$11.63 million	-0.14
Mymd Pharmaceuticals Competitors	$23.46 billion	$3.69 billion	4.84

Mymd Pharmaceuticals’ competitors have higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mymd Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1	0	0	0	1.00
Mymd Pharmaceuticals Competitors	1057	4270	7610	358	2.55

As a group, “Technology Hardware, Storage & Peripherals” companies have a potential upside of 23.95%. Given Mymd Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Mymd Pharmaceuticals has less favorable growth aspects than its competitors.

Risk & Volatility

Mymd Pharmaceuticals has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals’ competitors have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Profitability

This table compares Mymd Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Mymd Pharmaceuticals Competitors	-609.25%	-15.45%	3.05%

Institutional & Insider Ownership

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.3% of shares of all “Technology Hardware, Storage & Peripherals” companies are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of shares of all “Technology Hardware, Storage & Peripherals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mymd Pharmaceuticals competitors beat Mymd Pharmaceuticals on 11 of the 13 factors compared.

About Mymd Pharmaceuticals

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.